Lantern Pharma Inc (LTRN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.91+2.14%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LTRN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
LTRN — debt issuance
Dated 2026-05-14
Entry into a Material Definitive Agreement. On May 12, 2026, Lantern Pharma Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors, pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering (i) 1,454,175 shares (the “Common Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, at an offering price of $2.06 per share, and (ii) pre-funded warran…
Why it matters: New financing could help Lantern keep running and support its projects.
Supportive ifNews of more financing rounds or partnerships that improve cash flow.
Worry ifNot getting financing or bad market reactions to funding efforts.
Why it matters: Making an independent group could help get funding and increase the value of Lantern's AI.
Supportive ifOfficial news about the new group's formation and start of operations.
Worry ifDelay or stop of the plan to separate withZeta.ai into a new group.
Why it matters: This report will show if Lantern can maintain its reduced R&D costs while advancing its pipeline.
Watch forQ2 results show continued reduction in net loss and effective R&D spending.
Also watch forQ2 results show increased net loss or ineffective R&D spending.
Why it matters: Funding operating costs is key for Lantern's growth and stability soon.
Supportive ifThe company says it has raised over $2 million for its operating costs.
Worry ifThe company fails to get the needed funding for operating costs.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$316 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $841 loss on $10,000 · 8.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,576 loss on $10,000 · 75.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Funding for Open Medicine AI could enhance its growth and commercial potential.
Supportive ifOpen Medicine AI raised more than $5 million in funding.
Worry ifThere are no funding announcements or delays for Open Medicine AI.
Why it matters: Good feedback from the FDA could support LP-184's trial design and development.
Supportive ifFDA provides no objections to the proposed trial protocol for LP-184.
Worry ifThe FDA has serious concerns or objections about the trial protocol.
Why it matters: Making an independent AI group could bring new funding and growth.
Supportive ifThey announced the launch of the independent AI group or secured funding for it.
Worry ifNo progress or delays in creating the AI business entity.
Why it matters: New data may show that LP-300 works for some lung cancer patients.
Supportive ifNew data from the HARMONIC™ trial shows better survival for patients using LP-300.
Worry ifThe upcoming updates show no big change in survival rates.
Why it matters: Separating AI assets could bring new money and growth chances for Lantern Pharma.
Supportive ifNews says they will finish separating AI assets into a new company.
Worry ifNo progress or delays in the planned separation of AI assets.
Why it matters: Starting an independent AI business could bring new funding and growth chances.
Supportive ifThere is news of a partnership or funding for the new AI business.
Worry ifThere is no progress or delays in starting the independent AI business.
Why it matters: Funding operating costs is key for Lantern Pharma to keep running and growing.
Worry ifThere is a successful funding announcement that pays for operating costs in Q3 2026.
Less concerning ifThere is news about funding problems or not being able to pay operating costs.
Why it matters: Progress for LP-184 could improve its market chance in bladder cancer treatment.
Supportive ifEMA or FDA approval for ongoing trials or new indications for LP-184.
Worry ifSetbacks or delays in starting the trial for LP-184.
Why it matters: New data could show the treatment works and help with enrollment plans.
Supportive ifNew data shows better survival rates for patients with EGFR exon 21 L858R mutations.
Worry ifData shows no real improvement in results or side effects that may slow enrollment.
Why it matters: Starting this trial could validate Lantern's pipeline and expand its market reach.
Supportive ifAnnouncement of the trial starting and good early results from the LP-184 program.
Worry ifDelays in starting the trial or negative early results that could impact future funding.
Why it matters: Market and business model details can change interest and value.
Supportive ifA good call that shows a clear plan and strong market for Open Medicine AI.
Worry ifUnclear information or bad feedback during the call may raise doubts about the platform.